Celltrion (South Korea)

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 650 citations · Full text

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 601 citations · Full text

Physicochemical characterization of Remsima®

Soon Kwan Jung, Kyoung Hoon Lee, Jae Won Jeon et al. · mAbs · 2014 · 337 citations · Full text

Immunocytochemical Technique, Chemical Analysis, Antibody Products +22

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Cheol-Min Kim, Dong-Kyun Ryu, Jihun Lee et al. · Nature Communications · 2021 · 297 citations · Full text

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski et al. · Annals of the Rheumatic Diseases · 2016 · 278 citations · Full text